ATE387192T1 - Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht - Google Patents

Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht

Info

Publication number
ATE387192T1
ATE387192T1 AT98950401T AT98950401T ATE387192T1 AT E387192 T1 ATE387192 T1 AT E387192T1 AT 98950401 T AT98950401 T AT 98950401T AT 98950401 T AT98950401 T AT 98950401T AT E387192 T1 ATE387192 T1 AT E387192T1
Authority
AT
Austria
Prior art keywords
styrene
dermatological
plaster
producing
base layer
Prior art date
Application number
AT98950401T
Other languages
English (en)
Inventor
Kimihiro Fujii
Kazuo Tanaka
Kazuya Ikawa
Yasuhiro Ikeura
Shinji Yamasoto
Original Assignee
Bando Chemical Ind
Hisamitsu Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bando Chemical Ind, Hisamitsu Pharmaceutical Co filed Critical Bando Chemical Ind
Application granted granted Critical
Publication of ATE387192T1 publication Critical patent/ATE387192T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
    • B32B27/302—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising aromatic vinyl (co)polymers, e.g. styrenic (co)polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
    • B32B27/304—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising vinyl halide (co)polymers, e.g. PVC, PVDC, PVF, PVDF
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/36—Layered products comprising a layer of synthetic resin comprising polyesters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/40—Layered products comprising a layer of synthetic resin comprising polyurethanes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
    • B32B7/04—Interconnection of layers
    • B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2327/00—Polyvinylhalogenides
    • B32B2327/06—PVC, i.e. polyvinylchloride
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2367/00—Polyesters, e.g. PET, i.e. polyethylene terephthalate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2375/00—Polyureas; Polyurethanes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2556/00—Patches, e.g. medical patches, repair patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesive Tapes (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98950401T 1997-10-28 1998-10-26 Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht ATE387192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29510397 1997-10-28

Publications (1)

Publication Number Publication Date
ATE387192T1 true ATE387192T1 (de) 2008-03-15

Family

ID=17816342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950401T ATE387192T1 (de) 1997-10-28 1998-10-26 Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht

Country Status (11)

Country Link
US (1) US6267983B1 (de)
EP (1) EP0968711B9 (de)
JP (1) JP4395200B2 (de)
KR (1) KR100719273B1 (de)
CN (1) CN1152673C (de)
AT (1) ATE387192T1 (de)
AU (1) AU730850B2 (de)
CA (1) CA2275539A1 (de)
DE (1) DE69839179T2 (de)
TW (1) TW518228B (de)
WO (1) WO1999021537A1 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
DE60328496D1 (en) 2002-06-27 2009-09-03 Health Research Inc Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
EP2036908A3 (de) 2002-07-02 2009-05-13 Health Research, INC. Effiziente Synthese von Pyropheophorbid-A-Derivaten
MY138871A (en) * 2003-04-22 2009-08-28 Sumitomo Chemical Co Insect pest control heat vaporizing material
CA2525547C (en) * 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
RU2371440C2 (ru) 2004-05-20 2009-10-27 Дзе Скриппс Рисёч Инститьют Стабилизация транстиретина
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ554545A (en) 2004-09-17 2010-10-29 Whitehead Inst Of Biomedical R Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
JP4804007B2 (ja) * 2005-01-13 2011-10-26 日東電工株式会社 粘着製品
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
JP5036270B2 (ja) * 2005-12-02 2012-09-26 日東電工株式会社 加熱剥離型粘着シートおよびこの加熱剥離型粘着シートを用いた半導体チップの製造方法
AU2007245129A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
JP5209625B2 (ja) 2006-08-28 2013-06-12 協和発酵キリン株式会社 アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
EP2373693A4 (de) 2009-01-06 2012-04-25 Curelon Llc Zusammensetzungen und verfahren zur behandlung bzw. prävention von mundinfektionen durch e.coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8920392B2 (en) * 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2499282B1 (de) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-sekretase-modulierende verbindungen, verfahren zu ihrer identifikation und verwendungen dafür
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
IN2012DN04858A (de) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
USD631166S1 (en) 2010-05-27 2011-01-18 Leffew Helen C Transdermal patch with date stamp
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
CN103619348B (zh) 2011-04-21 2016-10-26 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
WO2012177962A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
EP2793580A4 (de) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc Neuartige isoergolinderivate
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
DK2844637T5 (en) 2012-05-02 2018-08-13 Boehringer Ingelheim Int SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS BY SSAO AND USES THEREOF
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP2852570B1 (de) 2012-05-23 2020-04-22 Cellixbio Private Limited Zusammensetzung zur behandlung von entzündlicher darmerkrankung
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (de) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazolderivate als hemmer von stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2016128991A1 (en) 2015-02-09 2016-08-18 Cellix Bio Private Limited Compositions and methods for the treatment of mucositis
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
WO2016067297A1 (en) 2014-10-27 2016-05-06 Cellix Bio Private Limited Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy
EP3212633B1 (de) 2014-10-31 2019-12-04 The General Hospital Corporation Wirksame gammasekretasemodulatoren
CA2969330A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
EP3237450B1 (de) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
CN107405346A (zh) 2015-01-20 2017-11-28 Xoc制药股份有限公司 异麦角灵化合物及其用途
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
EP3289104B1 (de) 2015-04-29 2020-11-04 New York University Verfahren zur behandlung von hochwertigen gliomen
KR20230028478A (ko) 2015-05-29 2023-02-28 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP4455145A3 (de) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
WO2017156183A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US11078154B2 (en) 2016-08-11 2021-08-03 Cellix Bio Private Limited Compositions and methods for the treatment of irritable bowel syndrome
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
CN110099681A (zh) 2016-10-04 2019-08-06 塞尔利克斯生物私人有限公司 用于治疗口腔干燥症的组合物和方法
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
EP3554494A4 (de) 2016-12-19 2021-02-17 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von entzündungen
US10513497B2 (en) 2017-02-17 2019-12-24 Eidos Therapeutics, Inc. Process for preparing AG-10, its intermediates, and salts thereof
US10961276B2 (en) 2017-02-17 2021-03-30 CAMRIS International, Inc. Universal antivenom
EP3609528A4 (de) 2017-04-10 2020-12-23 Curemark, LLC Zusammensetzungen zur suchtbehandlung
TW202500588A (zh) 2017-04-13 2025-01-01 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
MA50957A (fr) 2017-05-01 2020-10-14 Agenus Inc Anticorps anti-tigit et leurs méthodes d'utilisation
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load
EP3645040A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur krebsbehandlung
CN110972463B (zh) 2017-06-27 2024-05-28 纽洛可科学有限公司 抗序列相似家族19成员a5抗体在治疗青光眼中的用途
CN111315774B (zh) 2017-06-27 2023-12-22 纽洛可科学有限公司 抗fam19a5抗体及其用途
EP3645039A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur behandlung von fibrose
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
EP4265257A1 (de) 2017-09-01 2023-10-25 East Carolina University Kombination eines prostaglandin-ethanolamids der j-serie und eines checkpoint-inhibitors zur verwendung bei der behandlung von krebs
WO2019069229A1 (en) 2017-10-02 2019-04-11 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
EP3709982A4 (de) 2017-11-17 2021-10-13 Cellix Bio Private Limited Verbindungen, zusammensetzungen und verfahren zur behandlung von augenleiden und hautkrankheiten
JP7006990B2 (ja) 2017-11-17 2022-02-10 セリックス バイオ プライヴェート リミテッド 眼障害の処置のための組成物及び方法
AU2019239291A1 (en) 2018-03-23 2020-10-08 Eidos Therapeutics, Inc. Methods of treating TTR amyloidosis using AG10
CN112424223B (zh) 2018-04-24 2024-12-17 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
EP3790898A4 (de) 2018-05-10 2022-03-02 Neuracle Science Co., Ltd Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
MA53238A (fr) 2018-08-17 2022-04-13 Eidos Therapeutics Inc Formules d'ag10
EP3860713A2 (de) 2018-10-03 2021-08-11 Staten Biotechnology B.V. Antikörper spezifisch für menschliches und cynomolgus-apoc3 und verfahren zur verwendung davon
EP3867272A4 (de) 2018-10-16 2022-08-03 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
KR102757347B1 (ko) 2018-12-27 2025-01-23 주식회사 뉴라클사이언스 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
EP3906260A4 (de) 2019-01-02 2022-08-31 Neuracle Science Co., Ltd Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
EP3921038A1 (de) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
FI3930847T3 (fi) 2019-02-26 2024-04-23 Inspirna Inc Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
CN114222802B (zh) 2019-05-20 2025-07-11 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
CN119752217A (zh) 2019-05-20 2025-04-04 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
MX2022003166A (es) 2019-09-16 2022-06-29 Dice Alpha Inc Moduladores de il-17a y usos de los mismos.
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4232070A1 (de) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Verfahren zur induktion von stammzellenmobilisierung
EP4236989A1 (de) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Verwendung von interleukin-7 zur behandlung des coronavirus
EP4240408A1 (de) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus einem il-7-protein und einem nukleotidimpfstoff
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
JP2024539134A (ja) 2021-10-22 2024-10-28 プロセッタ バイオサイエンシズ， インク． 新規な宿主標的汎呼吸器抗ウイルス小分子治療薬
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
US20250099542A1 (en) 2021-12-30 2025-03-27 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
CA3268194A1 (en) 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. HETEROMERIC AGONIST ANTIBODIES DIRECTED AGAINST IL-18 RECEPTOR
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法
JP2026509512A (ja) 2023-03-17 2026-03-19 オキシトープ ファーマ ベー．フェー． 抗ホスホコリン抗体およびその使用方法
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN121127500A (zh) 2023-04-07 2025-12-12 达科纳治疗有限公司 针对激活素a受体样1型(alk1)的双特异性激动性抗体
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
CN121263415A (zh) 2023-05-09 2026-01-02 普罗根托斯治疗公司 杂环化合物及其用途
AU2024276812A1 (en) 2023-05-19 2025-11-06 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971753A (en) * 1973-12-13 1976-07-27 Union Carbide Corporation Polymer composites and preparation thereof
JPH02247118A (ja) * 1989-03-17 1990-10-02 Bando Chem Ind Ltd 皮膚貼付薬シート
JP2563846B2 (ja) * 1990-06-28 1996-12-18 バンドー化学株式会社 粘着シート
JPH0725665B2 (ja) * 1992-04-16 1995-03-22 バンドー化学株式会社 皮膚貼付薬シートの製造方法
JPH0733646A (ja) * 1993-07-23 1995-02-03 Bando Chem Ind Ltd 皮膚貼付薬シート
JP3485701B2 (ja) * 1995-11-06 2004-01-13 久光製薬株式会社 皮膚貼付用シート

Also Published As

Publication number Publication date
EP0968711A1 (de) 2000-01-05
EP0968711A4 (de) 2006-06-28
KR20000069728A (ko) 2000-11-25
EP0968711B1 (de) 2008-02-27
DE69839179T2 (de) 2009-02-19
EP0968711B9 (de) 2008-05-28
AU9648498A (en) 1999-05-17
CA2275539A1 (en) 1999-05-06
DE69839179D1 (de) 2008-04-10
AU730850B2 (en) 2001-03-15
US6267983B1 (en) 2001-07-31
WO1999021537A1 (fr) 1999-05-06
TW518228B (en) 2003-01-21
CN1247468A (zh) 2000-03-15
JP4395200B2 (ja) 2010-01-06
CN1152673C (zh) 2004-06-09
KR100719273B1 (ko) 2007-05-18

Similar Documents

Publication Publication Date Title
ATE387192T1 (de) Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht
TW354774B (en) Polymeric film and its method of production and use
CA2007163A1 (en) Pressure-sensitive film composite having improved adhesion to plasticized vinyl substrates
ATE173437T1 (de) Dekorative oberflächenschicht und verfahren zu deren herstellung
CA2185767A1 (en) A base fabric for air bags, a process for producing it and an air bag comprising it
ATE460275T1 (de) Dekorlaminat sowie verfahren zu dessen herstellung
EP1471126A3 (de) Druckempfindlicher Klebefilm oder druckempfindliches Klebeband sowie Verfahren zu deren Herstellung
CA2456170A1 (en) Multilayer microporous membrane
BR9401240A (pt) Folhas de polipropileno, processo e uso
CA2326961A1 (en) Backing for duct tapes
EP1057852A3 (de) Polyesterfolie für Dekorplatte oder Dekorschicht
CA2277348A1 (en) Curl-resistant, antislip abrasive backing and paper
CA2231397A1 (en) An architectural material and a process of production thereof
AU7633896A (en) Linoleum floor-covering
DE69730162D1 (de) Verfahren zum formen von dehnbaren schichtstoffstrukturen
KR960702798A (ko) 발포층을 갖는 장식 필름(decorative film having foaming layer)
ATE262929T1 (de) Klebefolie und klebstoffzubereitung und verfahren zur herstellung
EP1059325A3 (de) Poröse Folie
EP0330873A3 (de) Wärmerückstellbarer Gegenstand zum Umhüllen eines Substrates
DE50114349D1 (de) Biaxial orientierte polyolefinfolie mit verminderter blockneigung gegen kaltsiegelmassen
CA2426092A1 (en) Use of a polyolefin film as a medium to be written or printed on
DE59908770D1 (de) Verbundschichtplatte
CA2208396A1 (en) Foundation material for use with putty and manufacturing method therefor
ATE224809T1 (de) Verfahren zur herstellung eines laminats und dazu geeigneter, beschichter film
DE69924122D1 (de) Wärmeschrumpfbare folie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties